Bloomlife is a technology company.
Bloomlife has raised $30.0M across 4 funding rounds.
Bloomlife has raised $30.0M in total across 4 funding rounds.
Bloomlife has raised $30.0M in total across 4 funding rounds.
Bloomlife's investors include Buckley Ventures, LGF, Lowercarbon Capital, SOSV, Kapor Capital, CapitalG, Expa, Greylock, NEO, Next Play Ventures, Visionaire Ventures, Y Combinator.
# High-Level Overview
Bloomlife is a maternal health technology company that develops wearable sensors and connected care platforms to monitor high-risk pregnancies and improve birth outcomes.[1][2] Founded in 2014, Bloomlife pivoted from a direct-to-consumer model to a B2B2C approach, now serving healthcare providers and their pregnant patients through remote monitoring solutions.[1] The company has raised $12.2 million in total funding and operates with approximately 25 employees from its San Francisco headquarters.[3]
The company addresses a critical gap in maternal care by replacing manual, time-intensive monitoring processes with a comprehensive connected care platform that integrates with existing clinical workflows.[4] Bloomlife's core offering enables healthcare practices to monitor high-risk pregnancies remotely, reduce in-clinic appointments, automate administrative tasks, and provide clinicians with real-time data to make informed clinical decisions—ultimately working to reduce preventable pregnancy complications and improve maternal-fetal health outcomes.[2][4]
# Origin Story
Bloomlife was founded in 2014 by Eric Dy, PhD, and Julien Penders, MSc, with an explicit mission to improve birth outcomes.[1][2] The company emerged as one of the earliest FemTech companies on the market, initially launching a direct-to-consumer wearable contraction tracker—a sensor that measured uterine activity and affixed to the belly with adhesive patches, sending data to a smartphone app.[1]
The pivot point came through FDA engagement. After successfully shipping devices to over 14,000 mothers and building a proprietary dataset on uterine and fetal activity, Bloomlife developed an algorithm to identify labor onset with clinical-exam-level accuracy.[1] However, when the company began FDA discussions about expanding to preterm birth detection, the regulatory pathway shifted their strategy. The FDA would not support their existing product claims and marketing approach, prompting Bloomlife to cease consumer operations and redirect entirely toward a B2B2C healthcare provider model.[1] This regulatory inflection point transformed the company from a consumer-facing device maker into an enterprise software and services provider.
# Core Differentiators
# Role in the Broader Tech Landscape
Bloomlife operates at the intersection of three significant trends: the FemTech movement, the shift toward remote patient monitoring in healthcare, and the application of AI to clinical decision-making. As one of the earliest FemTech companies, Bloomlife helped pioneer the category and now benefits from increased investor and clinical attention to women's health innovation.
The company's evolution reflects a broader pattern in digital health: consumer-first models often encounter regulatory constraints that push them toward B2B healthcare provider partnerships, where clinical validation and integration with existing care systems become competitive advantages. Bloomlife's pivot demonstrates how regulatory engagement, rather than being purely restrictive, can redirect companies toward more sustainable, clinically embedded business models.
The maternal health space specifically faces a crisis—rising maternal mortality rates, particularly among underserved populations, and widespread maternity care deserts create urgent demand for solutions that improve access and quality of care. Bloomlife's remote monitoring platform directly addresses this need by enabling smaller practices and underserved clinics to provide high-risk pregnancy oversight without requiring specialized in-person infrastructure.
# Quick Take & Future Outlook
Bloomlife is positioned to become a foundational platform in maternal health infrastructure. The company's combination of proprietary data, validated AI models, and enterprise software integration creates defensible competitive advantages as healthcare systems increasingly adopt remote monitoring for high-risk populations.
The next phase likely involves expanding clinical validation through peer-reviewed research, broadening insurance coverage, and scaling adoption across healthcare networks—particularly in underserved regions. As maternal health gains prominence in healthcare policy and investment, Bloomlife's early-mover advantage in both technology and clinical partnerships positions it to influence how the broader healthcare system approaches pregnancy monitoring and risk stratification. The company's success will ultimately be measured not just by adoption metrics, but by its impact on birth outcomes and maternal mortality reduction.
Bloomlife has raised $30.0M across 4 funding rounds. Most recently, it raised $13.0M Series B in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $13.0M Series B | Buckley Ventures, LGF, Lowercarbon Capital, SOSV | |
| Jul 1, 2020 | $6.0M Series A | Kapor Capital | |
| Jul 1, 2018 | $5.0M Seed | CapitalG, Expa, Greylock, Kapor Capital, NEO, Next Play Ventures, Visionaire Ventures, Y Combinator, Adrian Aoun, Charlie Songhurst, Drew Houston, Farzad Nazem, Gabriel Naouri, Hadi Partovi, Henry Kravis, Jeff Bezos, Jeffrey Wilke, Nicolas Berggruen, Noosheen Hashemi, Shane Neman, Tom Chapman | |
| Aug 1, 2016 | $6.0M Seed | Act One Ventures, Battery Ventures, CapitalG, Expa, Greylock, Healthtech Capital, NEO, Next Play Ventures, Plug & Play Ventures, SOSV, Ulili, Visionaire Ventures, Y Combinator, Adrian Aoun, Charlie Songhurst, Drew Houston, Farzad Nazem, Gabriel Naouri, Hadi Partovi, Henry Kravis, Jeff Bezos, Jeffrey Wilke, Marc Benioff, Nicolas Berggruen, Noosheen Hashemi, Shane Neman, Tom Chapman |